SR-PSOX/CXCL16 plays a critical role in the progression of colonic inflammation

Gut

Volumn 60, Issue 11, 2011, Pages 1494-1505

  Uza, Norimitsu ^a   Nakase, Hiroshi ^a   Yamamoto, Shuji ^a   Yoshino, Takuya ^a   Takeda, Yasuhiro ^a   Ueno, Satoru ^a   Inoue, Satoko ^a   Mikami, Sakae ^a   Matsuura, Minoru ^a   Shimaoka, Takeshi ^b   Kume, Noriaki ^a   Minami, Manabu ^a   Yonehara, Shin ^a   Ikeuchi, Hiroki ^c   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM LYSATE; CXCL16 CHEMOKINE; DEXTRAN SULFATE; GAMMA INTERFERON; INTERLEUKIN 12; TRINITROBENZENESULFONIC ACID;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; COLITIS; CONTROLLED STUDY; CROHN DISEASE; CXCL16 BLOOD LEVEL; CYTOKINE PRODUCTION; DISEASE ACTIVITY; EX VIVO STUDY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; LAMINA PROPRIA; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS; UPREGULATION;

ADULT; ANIMALS; CHEMOKINE CXCL6; CHEMOKINES, CXC; COLON; CYTOKINES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-12; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, KNOCKOUT; MUCOUS MEMBRANE; PHAGOCYTOSIS; RECEPTORS, SCAVENGER; YOUNG ADULT;

EID: 80053574887     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.221879     Document Type: Article

References (43)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347:417-29. (Pubitemid 34851835)
2. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008;8:458-66. (Pubitemid 351733422)
3. Shih DQ, Targan SR, McGovern D. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep 2008;10:568-75.
4. Kamada N, Hisamatsu T, Okamoto S, et al. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J Immunol 2005;175:6900-8. (Pubitemid 41598935)
5. Nakase H, Okazaki K, Tabata Y, et al. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J Pharmacol Exp Ther 2000;292:15-21. (Pubitemid 30026351)
6. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-7. (Pubitemid 30398626)
7. Sallusto F, Mackay CR. Chemoattractants and their receptors in homeostasis and inflammation. Curr Opin Immunol 2004;16:724-31. (Pubitemid 39423660)
8. Bromley SK, Mempel TR, Luster AD. Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008;9:970-80.
9. Zimmerman NP, Vongsa RA, Wendt MK, et al. Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis 2008;14:1000-11.
10. Gijsbers K, Geboes K, van Damme J. Chemokines in gastrointestinal disorders. Curr Drug Targets 2006;7:47-64.
11. Shimaoka T, Kume N, Minami M, et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 2000;275:40663-6. (Pubitemid 32054881)
12. Matloubian M, David A, Engel S, et al. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000;1:298-304.
13. Wilbanks A, Zondlo SC, Murphy K, et al. Expression cloning of the STRL33/BONZO/ TYMSTR ligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001;166:5145-54. (Pubitemid 32280729)
14. Shimaoka T, Nakayama T, Kume N, et al. Cutting edge: SR-PSOX/CXC chemokine ligand 16 mediates bacterial phagocytosis by APCs through its chemokine domain. J Immunol 2003;171:1647-51. (Pubitemid 36966446)
15. Yamauchi R, Tanaka M, Kume N, et al. Upregulation of SR-PSOX/CXCL16 and recruitment of CD8+ T cells in cardiac valves during inflammatory valvular heart disease. Arterioscler Thromb Vasc Biol 2004;24:282-7. (Pubitemid 38197579)
16. Lehrke M, Millington SC, Lefterova M, et al. CXCL16 is a marker of inflammation, atherosclerosis, and acute coronary syndromes in humans. J Am Coll Cardiol 2007;49:442-9. (Pubitemid 46135882)
17. Wu T, Xie C, Wang HW, et al. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007;179:7166-75.
18. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
19. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6. (Pubitemid 19032930)
20. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
21. Andus T, Klebl F, Rogler G, et al. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther 2003;17:409-14. (Pubitemid 36259403)
22. Shimaoka T, Seino K, Kume N, et al. Critical role for CXC chemokine ligand 16 (SR-PSOX) in Th1 response mediated by NKT cells. J Immunol 2007;179:8172-9.
23. Cong Y, Brandwein SL, McCabe RP, et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998;187:855-64. (Pubitemid 28141659)
24. Inoue S, Nakase H, Matsuura M, et al. The effect of proteasome inhibitor MG 132 on experimental inflammatory bowel disease. Clin Exp Immunol 2009;156:172-82.
25. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
26. Shimaoka T, Nakayama T, Fukumoto N, et al. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol 2004;75:267-74. (Pubitemid 38174584)
27. Matsuura M, Okazaki K, Nishio A, et al. Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. Gastroenterology 2005;128:975-86. (Pubitemid 40523548)
28. Williams KL, Fuller CR, Dieleman LA, et al. Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 2001;120:925-37. (Pubitemid 32193189)
29. Elson CO, Beagley KW, Sharmanov AT, et al. Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. J Immunol 1996;157:2174-85. (Pubitemid 126449698)
30. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224-31. (Pubitemid 29044613)
31. Mikami S, Nakase H, Yamamoto S, et al. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis. J Pharmacol Exp Ther 2008;327:383-92.
32. Hase K, Murakami T, Takatsu H, et al. The membrane-bound chemokine CXCL16 expressed on follicle-associated epithelium and M cells mediates lympho-epithelial interaction in GALT. J Immunol 2006;176:43-51. (Pubitemid 43023247)
33. Sartor RB. Animal models of intestinal inflammation. In: Sartor RB, Sandborn WJ, eds. Kirsner's Inflammatory Bowel Disease. 6th edn. Edinburgh: Saunders, 2004:120-37.
34. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603. (Pubitemid 32531408)
35. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6. (Pubitemid 32531409)
36. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn's disease in ATG16L1. Nat Genet 2007;39:207-11. (Pubitemid 46184351)
37. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007;39:830-2. (Pubitemid 47014496)
38. Lehrke M, Konrad A, Schachinger V, et al. CXCL16 is a surrogate marker of inflammatory bowel disease. Scand J Gastroenterol 2008;43:283-8. (Pubitemid 351238351)
39. Wuttge DM, Zhou X, Sheikine Y, et al. CXCL16/SR-PSOX is an interferon-gregulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004;24:750-5. (Pubitemid 38451615)
40. Abel S, Hundhausen C, Mentlein R, et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-g and TNF-a and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004;172:6362-72. (Pubitemid 38621245)
41. Chandrasekar B, Mummidi S, Valente AJ, et al. The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling. J Biol Chem 2005;280:26263-77. (Pubitemid 41022224)
42. Kwon KH, Ohigashi H, Murakami A. Dextran sulfate sodium enhances interleukin-1 beta release via activation of p38 MAPK and ERK1/2 pathways in murine peritoneal macrophages. Life Sci 2007;81:362-71. (Pubitemid 47077428)
43. O'Connor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009;10:603-9.